Evaluation of CD8+ T-cell frequencies by the elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

International Journal of Cancer

Volumn 87, Issue 3, 2000, Pages 391-398

  Lewis, Jonathan J ^a   Janetzki, Sylvia ^a   Schaed, Susanne ^a   Panageas, Katherine S ^a   Wang, Siqun ^a   Williams, Linda ^a   Meyers, Michael ^a   Butterworth, Leah ^a   Livingston, Philip O ^a   Chapman, Paul B ^a   Houghton, Alan N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; NONAPEPTIDE; QS 21; TUMOR ANTIGEN;

ADULT; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ADULT; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PILOT PROJECTS; REFERENCE VALUES;

EID: 0034255724     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K     Document Type: Article

References (57)

1. ALTMAN, J.D., MOSS, P.A.H., GOULDER, P.J.R., BAROUCH, D.H., MCHEYZER-WILLIAMS, M.G., BELL, J.I., MCMICHAEL, A.J. and DAVIS, M.M., Phenotypic analysis of antigen-specific T lymphocytes. Science, 274, 94-96 (1998).
2. BAKKER, A.B., SCHREURS, M.W.J., DEBOER, A.J., KAWAKAMI, Y., ROSENBERG, S.A., ADEMA, G.J. and FIGDOR, C.G., Melanocyte-lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179, 1005-1009 (1994).
3. BRICHARD, V., VAN PEL, A., WÖLFEL, T., WÖLFEL, C., DEPLAEN, E., LETHE, B., COULIE, P. and BOON, T., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178, 489-495 (1993).
4. BRICHARD, V.G., HERMAN, J., VAN PEL, A., WILDMANN, C., GAUGLER, B., WÖLFEL, T., BOON, T. and LETHE, B., A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Europ. J. Immunol., 26, 224-230 (1996).
5. BUTZ, E.A. and BEVAN, M.J., Massive expansion of antigen-specific CD8-positive T cells during an acute viral infection. Immunity, 8, 167-175 (1998).
6. CHEN, Y.T., STOCKERT, E., TSANG, S., COPLAN, K.A. and OLD, L.J., Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. nat. Acad Sci. (Wash.), 92, 8125-8129 (1995).
7. CORMIER, J.N., ABATI, A., FETSCH, P., HIJAZI, Y.M., ROSENBERG, S.A., MARINCOLA, F.M. and TOPALIAN, S.L., Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother., 21, 27-31 (1998).
8. COULIE, P.G., SOMVILLE, M., LEHMANN, F., HAINAUT, P., BRASSEUR, F., DEVOS, R. and BOON, T., Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer, 50, 289-297 (1992).
9. COULIE, P.G., WEYNANTS, P., LEHMANN, F., HERMAN, J., BRICHARD, V., WÖLFEL, T., VAN PEL, A., DE PLAEN, E., BRASSEUR, F. and BOON, T., Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J. Immunother., 14, 104-109 (1993).
10. CZERKINSKY, C., ANDERSSON, G., EKRE, H.-P., NILSSON, L.-A., KLARESKOG, L. and OUCHTERLONY, O., Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Meth., 110, 29-36 (1988).
11. + melanoma patients have a memory phenotype. Int. J. Cancer, 78, 699-706 (1998).
12. DE VRIES, T.J., FOURKOUR, A., WOBBES, T., VERKROOST, G., RUITER, D.J. and VAN MIJEN, G.N., Heterogenous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57, 3221-3229 (1997).
13. DUHRA, P. and ILCHYSHYN, A., Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin. Exp. Dermatol., 16, 303-305 (1991).
14. DUNBAR, P.R., OGG, G.S., CHEN. J., RUST, N., VAN DER BRUGGEN, P. and CERUNDOLO, V., Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol., 8, 413-416 (1998).
15. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol., 162, 1780-1788 (1999).
16. HARA, I., TAKECHI, Y. and HOUGHTON, A.N., Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med., 182, 1609-1614 (1995).
17. + T lymphocytes secreting tumor-necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Meth., 191, 131-142 (1996).
18. HOUGHTON, A.N., EISINGER, M., ALBINO, A.P., CAIRNCROSS, J.G. and OLD, L.J., Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med., 156, 1755-1766 (1982).
19. HOUGHTON, A.N., REAL, F.X., DAVIS, L.J., CORDON-CARDO, C. and OLD, L.J., Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J. Exp. Med., 165, 812-829 (1987).
20. HOUGHTON, A.N., Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180, 1-4 (1994).
21. JÄGER, E., RINGHOFFER, M., ARAND, M., KARBACH, J., JÄGER, D., ILSEMANN, C., HAGEDORN, M., OESCH, F. and KNUTH, A., Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res., 6, 419-425 (1996a).
22. JÄGER, E., RINGHOFFER, M., DIENES, H.P., ARAND, M., KARBACH, J., JÄGER, D., ILSEMANN, C., HAGEDORN, M., OESCH, F. and KNUTH, A., Granulocytemacrophage-colony-stimulating factor enhances immune response to melanoma-associated peptides in vivo. Int. J. Cancer, 67, 54-62 (1996b).
23. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66, 470-476 (1996c).
24. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANELLI, J.R., APELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltration lymphocytes. J. Exp. Med., 180, 347-352 (1994a).
25. KAWAKAMI, Y., ELIYAHU, S., DELGADO, C.H., ROBBINS, P.F., SAKAGUCHI, K., APPELLA, E., YANELLI, J.R., ADEMA, G.J., MIKI, T. and ROSENBERG, S.A., Identification of a human melanoma antigen recognized by tumor-infiltration lymphocytes associated with in vivo tumor rejection. Proc. nat. Acad. Sci. (Wash.), 91, 6458-6462 (1994b).
26. KITTLESEN, D.J., THOMPSON, L.W., GULDEN, P.H., SKIPPER, J.C., COLELLA, T.A., SHABANOWITZ, J.A., HUNT, D.F., ENGELHARD, V.H. and SLINGLUFF, C.L. JR., Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J. Immunol., 160, 2099-2106 (1998).
27. + memory T cells. J Exp. Med., 186, 859-865 (1997).
28. LARSSON, M., JIN, X., RAMRATNAM, B., OGG, G.S., ENGELMAYER, J., DEMOITIE, M.A., MCMICHAEL, A.J., COX, W.I., STEINMAN, R.M. NIXON, D. and BHARDWAJ, N., A recombinant vaccinia virus based Elispot assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS, 13, 767-777 (1999).
29. LEE, P.P., YEE, C., SAVAGE, P.A., FONG, L., BROCKSTEDT, D., WEBER, J.S., JOHNSON, D., SWETTER, S., THOMPSON, J., GREENBERG, P.D., ROEDERER, M. and DAVIS, M.M., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5, 677-685 (1999).
30. LEWIS, J.J. and HOUGHTON, A.N., Definition of tumor antigens for vaccine construction. Sem. Cancer Biol., 6, 321-327 (1996).
31. LEWIS, J.J. and JANETZKI, S., A new hotspot for cancer immunotherapy? Cancer J. Sci. Amer., 4, 298-299 (1998).
32. LOFTUS, D.J., CASTELLI, C., CLAY, T.M., SQUARCINA, P., MARINCOLA, F.M., NISHIMURA, M.I., PARMIANI, G., APPELLA, E. and RIVOLTINI, L., Identification of epitope mimics recognized by CTL reactive to the melanocyte-derived peptide MART-1. J. Exp. Med., 184, 647-657 (1996).
33. MAHANTY, S., ABRAMS, J.S., KING, C.L., LIMAYE, A.P. and NUTMAN, T.B., Parallel regulation of IL-4 and IL-5 in human helminth infections. J. Immunol., 148, 3567-3571 (1992).
34. MARINCOLA, F.M., RIVOLTINI, L., SALGALLER, M.L., PLAYER, M. and ROSENBERG, S.A., Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother. Emphasis Tumor Immunol., 19, 266-277 (1996).
35. MAZZOCCHI, A., BELLI, F., MASCHERONI, L., VEGETTI, C., PARMIANI, G. and ANICHINI, A., Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer, 58, 330-339 (1994).
36. + T cells using an Elispot assay. J. Immunol. Meth., 181, 45-54 (1995).
37. MURALI-KRISHNA, K., ALTMAN, J.D., SURESH, M., SOURDIVE, D.J.D., ZAJAC, A.J., MILLER, J.D., SLANSKY J. and AHMED R., Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity, 8, 177-187 (1998).
38. NAFTZGER, C., TAKECHI, Y., KOHDA, H., HARA, I., VIJAYASARADHI, S. and HOUGHTON, A.N., Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. nat. Acad. Sci. (Wash.), 93, 14809-14814 (1996).
39. NANDA, N.K. and SERCARZ, E.E., Induction of anti-self-immunity to cure cancer. Cell. 82, 13-17 (1995).
40. PASS, H.A., SCHWARZ, S.L., WUNDERLICH, J.R. and ROSENBERG, S.A., Immunization of patients with melanoma peptide vaccines: immunologic assessment using the Elispot assay. Cancer J. Sci. Amer., 4, 316-323 (1998).
41. RICHARDS, J.M., MEHTA, N., RAMMING, K. and SKOSEY, P., Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol., 10, 1338-1343 (1992).
42. ROSENBERG, S.A. and WHITE, D.E., Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol., 19, 81-84 (1996).
43. ROSENBERG, S.A. and 15 OTHERS, Immunological and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998).
44. SCHALLREUTER, K.U., LEVENIG, C. and BERGER, J., Vitiligo and cutaneous melanoma: a case study. Dermatologica, 183, 239-245 (1991).
45. SCHMITTEL, A., KEILHOLZ, U. and SCHEIBENBOGEN, C., Evaluation of the interferon-gamma Elispot-assay for quantification of peptide-specific T lymphocytes from peripheral blood. J. Immunol. Meth. 210, 167-174 (1997).
46. SIROTT, M.N., BAJORIN, D.F., WONG, G.Y., TAO, Y., CHAPMAN, P.B., TEMPLETON, M.A. and HOUGHTON, A.N., Prognostic factors in patients with metastatic malignant melanoma. A multivariart analysis. Cancer, 72, 3091-3098 (1993).
47. SKIPPER, J.C., HENDRICKSON, R.C., GULDEN, P.H., BRICHARD, V., VANPEL, A., CHEN, Y., SHABANOWITZ, J., WÖLFEL, T., SLINGLUEF, C.L. JR., BOON, T., HUNT, D.F. and ENGELHARD, V.H., An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med., 183, 527-534 (1996).
48. SONG, Y.H., CONNOR, E., LI, Y., ZOROVICH, B., BALDUCCI, P. and MACLAREN, N., The role of tyrosinase in autoimmune vitiligo. Lancet, 344, 1049-1052 (1994).
49. + T cells specific for EBV in healthy virus carriers. J. Immunol., 162, 1827-1835 (1999).
50. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med ., 183, 1965-1671 (1996).
51. + alpha beta T cell and gamma delta T cell responses to Mycobacterium tuberculosis. Similarities and differences in recognition, cytotoxic effector function and cytokine production. J. Immunol., 154, 1786-1796 (1995).
52. VIJAYASARADHI, S., BOUCHARD, B. and HOUGHTON, A.N., The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med., 171, 1375-1380 (1990).
53. VISSEREN, M.J., VAN ELSAS, A., VAN DER VOORT, E.I., RESSING, M.E., KAST, W.M., SCHRIER, P. and MELIEF, C.J., CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol., 154, 3991-3998 (1995).
54. WEBER, L.W., BOWNE, W.B., WOLCHOK, J.D., SRINIVASAN, R., QIN, J., MOROI, Y., CLYNES, R., SONG, P., LEWIS, J.J. and HOUGHTON, A.N., Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest., 102, 1258-1264 (1998).
55. WÖLFEL, T., VAN PEL, A., BRICHARD, V., SCHNEIDER, J., SELIGER, B., MEYER ZUM BÜSCHENFELDE, K.-H. and BOON, T., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Europ. J. Immunol., 24, 759-764 (1994).
56. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol., 157, 4079-4086 (1996).
57. YI, Q. and LEFVERT, A.K., Idiotypic and antiidiotypic T and B lymphocytes in myasthenia gravis. J. Immunol., 149, 3423-3426 (1992).